2023
ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA
Amengual J, Shyr Y, Durecki D, Beumer J, Mansukhani M, Williams M, Kelleher N, Cherng H, Pro B, Schwartz G, LoRusso P, Piekarz R. ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA. Hematological Oncology 2023, 41: 833-834. DOI: 10.1002/hon.3166_ot14.Peer-Reviewed Original Research
2019
Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3 mut+) Acute Myeloid Leukemia (AML)
Zeidan A, Qi C, Pandya B, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3 mut+) Acute Myeloid Leukemia (AML). Blood 2019, 134: 3859. DOI: 10.1182/blood-2019-123819.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationEvent-free survivalAcute myeloid leukemiaIncremental cost-effectiveness ratioUS third-party payer perspectiveThird-party payer perspectiveProbabilistic sensitivity analysesSalvage chemotherapyADMIRAL trialOverall survivalEfficacy inputsDeterministic sensitivity analysesIncremental costPayer perspectiveLifetime horizonAllogeneic hematopoietic stem cell transplantationFavorable cost-effectiveness profileHealth statesPost-progression treatmentTerminal care costsTreatment of RelapsedActive treatment optionsEffective therapeutic optionLong-term survivorsTreatment costs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply